ArticleGynecology and pelvic medicine2026
Causal associations between plasma proteins and premature ovarian failure through multi-omics Mendelian randomization analyses.
Article in Gynecology and pelvic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Premature ovarian failure (POF), an endocrine disorder with ovarian dysfunction before age 40 years, severely affects fertility and health. This study aims to elucidate the genetic association of POF through plasma protein profiling to identify potential therapeutic targets. Methods: Using genetic instruments derived from the UKB-PPP and eQTLGen, two-sample Mendelian randomization (MR) analysis was conducted to systematically identify significant causal associations between plasma proteins and POF at both the gene expression and protein levels. Additional analytical approaches, including summary-data-based MR (SMR), heterogeneity in dependent instruments (HEIDI) testing, Bayesian co-localization, and a series of sensitivity analyses, were also employed to further validate the robustness of the findings. Subsequently, mediation analysis was performed to explore potential pathways through which plasma proteins may influence POF via immune or metabolic intermediaries. Finally, a phenome-wide MR analysis (MR-PheWAS) was conducted to assess the potential pleiotropic effects of the identified proteins. Results: Our analysis identified 96 proteins exhibiting causal relationship with POF. Notably, C-C motif chemokine 23 (CCL23) and tumor necrosis factor receptor superfamily member 14 (TNFRSF14) emerged as protective factors. Validation through SMR and HEIDI tests confirmed significant associations for 58 proteins. Bayesian colocalization further provided moderate evidence of colocalization for CCL23 [posterior probability for H4 (PP.H4) =72.1%] and TNFRSF14 (PP.H4 =54.9%). Additionally, mediation analysis revealed that immune cell traits and metabolic factors play crucial roles in POF development. MR-PheWAS demonstrated that CCL23 and TNFRSF14 are associated with various phenotypes, suggesting their broader implications beyond POF. Conclusions: This study identifies CCL23 and TNFRSF14 as putative causal mediators of POF, revealing their potential as dual therapeutic targets and providing novel insights into the underlying mechanisms of POF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.